Abstract
Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Current Pharmaceutical Design
Title: Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Volume: 16 Issue: 26
Author(s): Kursat Tigen and Cihan Cevik
Affiliation:
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Abstract: Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Export Options
About this article
Cite this article as:
Tigen Kursat and Cevik Cihan, Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?, Current Pharmaceutical Design 2010; 16 (26) . https://dx.doi.org/10.2174/138161210793176473
DOI https://dx.doi.org/10.2174/138161210793176473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microcirculation and Heart Failure
Current Pharmaceutical Design The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry The Role of Calcium and the L-Type Calcium Channel in Pathological Remodeling of the Heart
Vascular Disease Prevention (Discontinued) Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Roles of Perilipins in Diseases and Cancers
Current Genomics PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews